Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity. By inhibiting factor Xa, apixaban prevents thrombin generation and thrombus development.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
$substanceName is the active ingredient of these drugs:
Ecuador Estonia Lithuania Poland
Estonia
Estonia
Ecuador
Australia Austria Brazil Canada Cyprus
Tunisia
Ecuador
Ecuador
Poland
South Africa
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):